cst = high risk, page-7

re: cst = sales CST said they expected Japan before last september. Unfortunately NO-ONE knows anything about japanese approval timing as it has always been a lottery in the past. One thing is certain though and that is they will recieve approval, definitely before May, as this is when the "NEW" focus on TB eradication will be launched as many of the japanese "thought leaders" are alluding to.
No real drop in sp as share parcel allocations were only small and most are hanging on for the medium term upside which "in-house" expects the sp to exceed $10.00. Even if they perform poorly in Japan and get only 20% of Tests, this equates to 3 million tests @ $8 profit per test = $32 million revenue a year from japan alone. P/E of 20 equates to Share price of approx $8.00. Look on the bright side. If the sp does head toward $2.40 then put everything you own into it. This is the reason they are capitolised at 1/4 billion when their last 1/4 sales were only $350K